Name: Flora, Rhodalyn & Lacanin, Janet Date:
Activity No. 8
The Internet and Other Sources of Information
Application

I. Objectives a. To describe the internet as information source b. To Cite applications and limitations of computer aided instructions c. List websites and the relevant drug or health – related information

II. Procedure a. Go to the Internet Library b. Log on the computer. c. Research. d. Answer the following questions

III. Questions: * Give what is asked of the following * Give their relevance to the pharmacy practice * Give the website where you found them

a. What are the FDA-Approved Anti-HIV Medications?
Antiretroviral therapy (ART) is the recommended treatment for HIV infection. ART involves taking a combination of anti-HIV medications (a regimen) daily. A regimen contains three or more anti-HIV medications from at least two different drug classes. Anti-HIV medications prevent HIV from multiplying in the body, which helps people infected with HIV live longer, healthier lives. ART may reduce the risk of transmission of HIV but anti-HIV medications can't cure HIV/AIDS.
The following table lists anti-HIV medications approved by the U.S. Food and Drug Administration (FDA) for treatment of HIV in the United States. The medications are presented by drug class and identified by generic name/acronym and brand name.

Drug Class | Generic Name (Acronym) | Brand Name | Manufacturer | FDA Approval Date | Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) | NNRTIs bind to and alter reverse transcriptase, an enzyme HIV needs to make copies of itself. | Delavirdine (DLV) | Rescriptor | Pfizer | April 4, 1997 | | Efavirenz (EFV) | Sustiva | Bristol-Myers Squibb | Sept. 17, 1998 | | Etravirine (ETR) | Intelence | Tibotec | Jan. 18, 2008 | | Nevirapine (NVP) | Viramune | Boehringer Ingelheim | June 21, 1996 | | Rilpivirine (RPV) | Edurant | Tibotec Therapeutics | May 20, 2011 | Nucleoside Reverse Transcriptase Inhibitors (NRTIs) | NRTIs block reverse transcriptase, an enzyme HIV needs to make copies of itself. | Abacavir (ABC) | Ziagen | GlaxoSmithKline | Dec. 17, 1998 | | Didanosine (ddI) | Videx
Videx EC (enteric-coated) | Bristol-Myers Squibb
Bristol-Myers Squibb | Oct. 9, 1991
Oct. 31, 2000 | | Emtricitabine (FTC) | Emtriva, Coviracil | Gilead Sciences | July 2, 2003 | | Lamivudine (3TC) | Epivir | GlaxoSmithKline | Nov. 17, 1995 | | Stavudine (d4T) | Zerit | Bristol-Myers Squibb | June 24, 1994 | | Tenofovir DF (TDF) | Viread | Gilead Sciences | Oct. 26, 2001 | | Zidovudine (ZDV, AZT) | Retrovir | GlaxoSmithKline | March 19, 1987 | Protease Inhibitors (PIs) | PIs block HIV protease, an enzyme HIV needs to make copies of itself. | | | | | | Atazanavir (ATV) | Reyataz | Bristol-Myers Squibb | June 20, 2003 | | Darunavir (DRV) | Prezista | Tibotec | June 23, 2006 | | Fosamprenavir (FPV) | Lexiva | GlaxoSmithKline, Vertex Pharmaceuticals | Oct. 20, 2003 | | Indinavir (IDV) | Crixivan | Merck | March 13, 1996 | | Nelfinavir (NFV) | Viracept | Agouron Pharmaceuticals | March 14, 1997 | | Ritonavir (RTV) | Norvir | Abbott Laboratories | March 1, 1996 | | Saquinavir (SQV) | Invirase | Hoffmann-La Roche | Dec. 6, 1995 | | Tipranavir (TPV) | Aptivus | Boehringer Ingelheim | June 22, 2005 | Fusion Inhibitors | Fusion inhibitors block HIV from entering the CD4 cells of the immune system. | Enfuvirtide (T-20) | Fuzeon | Hoffmann-La Roche, Trimeris | March 13, 2003 | CCR5 Antagonists | CCR5 entry inhibitors block CCR5, a protein on the CD4 cells that HIV needs to enter the cells. | Maraviroc (MVC) | Selzentry | Pfizer | Aug. 6, 2007 | Integrase Inhibitors | Integrase inhibitors block HIV integrase, an enzyme HIV needs to make copies of itself. | Raltegravir (RAL) | Isentress | Merck | Oct. 12, 2007 | Fixed-Dose Combination | Fixed-dose combination